McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Cerner (CERN) Strong on EHR Prospects, Competition Intense
by Zacks Equity Research
Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.
Cardinal Health Product Spectrum Broad, Competition Rife
by Zacks Equity Research
Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.
Allscripts' Payerpath & ePrescribe Receive EHNAC Accreditation
by Zacks Equity Research
Accreditation by EHNAC indicates Allscripts' (MDRX) sustainability in health data processing and transactions in terms of industry-established standards and HIPAA regulations.
Allscripts Gains From Strong Results in Q2, Competition Rife
by Zacks Equity Research
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
by Zacks Equity Research
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
McKesson's (MCK) Q1 Earnings Beat Estimates, Sales Improve Y/Y
by Zacks Equity Research
McKesson???s Q1 results were driven by solid performance in Medical-Surgical Solutions segment.
McKesson (MCK) Q1 Earnings Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.35% and -0.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
by Zacks Equity Research
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
Will 5 Elements Drive Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.
Will Flagship Impella Drive Abiomed's (ABMD) Q1 Earnings?
by Zacks Equity Research
Abiomed's (ABMD) first-quarter fiscal 2019 earnings are likely to be driven by an exclusive Impella product line. Intense competition raises concern.
Can International Sales Drive Baxter's (BAX) Q2 Earnings?
by Zacks Equity Research
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?
by Zacks Equity Research
Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.
Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?
by Zacks Equity Research
Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.
Should Value Investors Consider McKesson (MCK) Stock Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
McKesson (MCK) Issues Strong Preliminary Results for Q1
by Zacks Equity Research
McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.
Why Is McKesson (MCK) Up 1.7% Since Its Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson's (MCK) Q4 Earnings Miss Estimates, Sales Improve Y/Y
by Zacks Equity Research
McKesson (MCK) witnesses strong growth in its Distribution Solutions segment in Q4 of fiscal 2018.
Is McKesson Corporation (MCK) a Suitable Value Stock Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Top Stock Reports for Lockheed Martin, Mastercard & Colgate
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), Mastercard (MA) and Colgate (CL).
McKesson (MCK) Beats on Earnings and Sales in Q3
by Zacks Equity Research
McKesson Corporation (MCK) delivers strong performance on the back of solid organic growth.
McKesson (MCK) Beats on Earnings and Sales in Q2
by Zacks Equity Research
McKesson's adjusted earnings of $3.28 per share came above the Zacks Consensus Estimate of $2.78 and increased from $2.96 in the year-ago quarter.
Should You Buy McKesson Corporation (MCK) Ahead of Earnings?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.